For those capable of understanding, who do the research on deprenyl, and have an intricate insights into the aging process know deprenyl and CR diet are the most proven means of increasing lifespan in animals and hold the best promise of compounds currently available for helping to increase lifespan in humans.
While few studies on supplements have shown a maximum lifespan effect (partly because very few people fund the research) the drug deprenyl has been studied with healthy mice showing an effect of increasing maximum lifespan.(1,2, see http://www.imminst.o...&f=199&t=384&s= for more research)
I actually already brought this up in a thread (without anyone responding), but.. Michael, for example brought very reasonable sounding severe criticism on deprenyl on another thread here. So again, what is your response to that?
http://www.imminst.o...t=0quotes:
Deprenyl is often cited as a counterexample, but it really isn't. Yes, Knoll made an exciting single report (and repeated it in several journals), but he's the ONLY person to report an extension of max LS: lots of others show increases in av'g bu t not max, no extension at all, or even *increased* mortality. Flat ad hominem: Knoll had the patent on the stuff. See the desperate attempts to reconcile the data between different studies on pp. 3-8, esp. the lifespan discussions on pp 7-8, of (1). Much of this info (but without, alas, the unpublished stuff sumarized in (1)) is put in a tabular form in (2), which makes the fundamental lack of anything like a logical pattern in the results clear. IMO, this shows pretty clearly that even if you believe there's something to it as a life-extension drug, there is just no way that one can rationally USE it as such at this time as there is no basis upon which to reasonably extrapolate a dose which can be expected to consistently extend even AV'G LS in humans.
There are no trials in normal, healthy humans, & the studies in both early and late PD are in sum quite inconclusive on the safety of deprenyl. See:
http://groups.google.....4A@aimnet.com
http://groups.google.....BC@aimnet.com
http://groups.google.....84@aimnet.com
http://bmj.com/cgi/c...ll/317/7153/252
http://bmj.com/cgi/c...l/316/7139/1191
http://groups.google...m&output=gplain
(The first 3 largely go over the same ground, albeit from slightly
different angles; the others cover newer material).
..........................
It doesn't appear to give any reliable benefits in animal systems; it seems to kill the folks it's designed to TREAT; I just do not see how the risk:benefit calculation can be fudged to make it come out in favor of use by young, healthy people.
So when I say that "Knoll made an exciting single report (and repeated it in several journals), but he's the ONLY person to report an extension of max LS: lots of others show increases in av'g bu t not max, no extension at all, or even *increased* mortality", I'm referring to this failure to extend the normal, healthy organism's lifespan, not to the alleviation of premature mortality in short-lived strains or animals raised under poor husbandry. It's easy to reduce mortality by antioxidants in short-lived strains or chorts -- it's been done with any number of compounds, from Harnam on -- and deprenyl has certainly been reported to do this several times, although (again) it has also increased mortality in others (eg (6)).
That does not seem like strong case for deprenyl at all, it might actually be a life shortening drug. The two papers you refer to, actually relying on the ONE same study, were made by the patent owner of deprenyl J. Knoll (expliting also other questionable scientific behaviour, making one very suspicious of any results made by him regarding deprenyl). Despite rigorous efforts by other researchers, the max life extension could not be achieved again. Instead what was gotten were mixed results of increased average life span, no increase of anything and DECREASE of lifespan. Furthermore, there has been serious question about the safety of deprenyl on humans based on PD studies.
also
For those capable of understanding, who do the research on deprenyl, and have an intricate insights into the aging process know deprenyl
regarding this aspect:
A recent editorial comment on the study from which the last post is
abstracted:
http://www.neurology...s/55/12/1785#29
"Laboratory studies suggest that selegiline has properties that
theoretically could confer neuroprotection; however, evidence for this
in clinical trials is unfortunately lacking. ... Prescribing
medications such as selegiline on faith, with little evidence-based
efficacy, IGNORES THE NEGATIVE SIDE EFFECTS OF THIS PRACTISE, including
unnecessary expense to the patient, and the potential of deleterious
drug interations. (ref. 14)." The comment seems especially relevant in
the present discussion.
Also, basing such long term intervention only on theoretical arguments without having actual clinical proof could be very unwise. Theories change, we should expect clinical results (if such are obtainable) rather than only theoretical arguments. Are you for example aware of the thread I started regarding the essential function of ROS and possibly already optimized anti-oxidant defense in mammals?
http://www.imminst.o...394In the next paper they created a Drosophila strain with high levels of antioxidants and a lower production of ROS. Interestingly, the animals actually live less than controls:
http://www.ncbi.nlm....61&query_hl=112
This seems to support the idea that ROS are not just damaging compounds, but essential biological molecules used in a myriad of functions. On this subject, I have a paper on ROS that could be of interest to some of you:
http://www.ncbi.nlm....03&query_hl=116
Lastly, here's another recent paper showing that antioxidant protection does not correlate with longevity in rodents, in line with many other results suggesting that antioxidant protection is already optimized in mammals:
http://www.ncbi.nlm....18&query_hl=112
Aubrey confirmed the results regarding ROS production(on a PM to me asking to comment the results, I'm sure he won't mind me reproducing his reply):
Thing is, this is not news -- roles of ROS (and not just nitric oxide) in signalling have been kown for over a decade (check out Sue Goo Rhee in PubMed). I have cited this sort of work quite often in my papers as reasons for focusing on removal of accumulating but initially inert molecules and cells rather than removal or bioactive ones.
While this may not be news for Aubrey, it's certainly news for many people, for example Jaoa, me and I'm sure to plenty of other ImmInst members. I'm not sure if this conflicts with the theoretical argument for example of R-ALA, because I do not know the actual mechanism of R-ALA. From my understanding (correct me if I'm wrong), based on these results, a substance that decreases ROS production also in bioactive cells (and not only in inert cells), rather than only making the oxidative stress by ROS production to other cells less harmful, might have a life decreasing effect. This would be caused by intefering with essential signalling systems. But again, I'm not sure whether R-ALA acts through such mechanism, but it might (does anyone have a better understanding of these issues?). But I do know that at least for ALA the conducted rodent longevity studies have not been positive [1] (and not in my understanding for R-ALA either)
[1]Lee CK, Pugh TD, Klopp RG, Edwards J, Allison DB, Weindruch R, Prolla TA. The impact of alpha-lipoic acid, coenzyme Q10 and caloric restriction on life span and gene expression patterns in mice.Free Radic Biol Med. 2004 Apr 15;36(8):1043-57.
http://www.ncbi.nlm....5&dopt=CitationPS:Somebody please fix the bugs on this f***ing editor! [ang]
Edited by opales, 05 November 2005 - 01:22 PM.